CO-CSG
Communication service providers (CSPs) are racing to modernize their operations and deliver dynamic and personalized experiences for their customers. To leverage automation, intelligence and orchestration, they’re working to improve the customer experience across all touchpoints. In 2023, CSG® (NASDAQ: CSGS)’s award-winning solutions and integrated omnichannel approach helped global brands transform their customer experience, earning CSG recognition from leading analyst firms Gartner, Frost & Sullivan, Kaleido Intelligence, MGI and Quadrant Knowledge Solutions.
In recent months, CSG has been recognized as:
-
A Niche player in the 2023 Gartner® Magic Quadrant™ for Configure, Price and Quote Application Suites
- CSG Quote & Order enables CSPs to configure products with live pricing, creating comprehensive orders that seamlessly flow from quotes to fulfillment. An API-powered CPQ solution built for complex B2B services, it provides CSPs with the composability and order management capabilities they need to drive faster time to revenue and deliver a better overall customer experience.
-
A Leader in the 2023 Frost Radar for 5G Revenue Management and Monetization
- CSG enables CSPs to reduce reliance on multi-vendor solutions, lowering time to market and total cost of ownership by integrating charging, billing, policy control and interconnect. The depth of its capability portfolio, modular SaaS platforms and unique partnership-driven approach earn CSG a leadership placement for its ability to monetize a variety of 5G use cases on a single SaaS platform.
- Frost & Sullivan writes: "CSG has proven how it can integrate assets from a network and a messaging portfolio to provide a one-stop shop for CSPs. The company has mastered the challenges of hybrid operations."
-
A Leader in the 2023 MGI 360 Rating: The Agile Billing Top 50 Buyers Guide
- MGI recognized CSG Ascendon as “a good fit for organizations looking to create modern monetization capability to support new business initiatives”. The report states: "CSG Ascendon represents a multi-tenant SaaS approach to monetization tools for B2C-oriented digital services. It has a sophisticated product catalog capability, can support customer and product hierarchies and abstract complex pricing methods, including usage."
-
A Champion in the 2023 Kaleido Intelligence Roaming Vendor Hub – Clearing & Settlement
- CSG Retail Roaming Management platform enables CSPs to build new dynamic digital wholesale services and to drive the associated business models over 4G and 5G networks of any size. Kaleido notes: The CSG platform is "agile and extensible, bringing significant new functionality with minimal disruption to existing infrastructure."
- CSG was also recognized as a High-Flyer in the Roaming Analytics & VAS and Fraud Management rating categories.
-
A Leader in the 2023 SPARK Matrix: Configure, Price & Quote
- CSG Quote & Order helps service providers deliver complex digital offerings by addressing the dual challenges of B2B2X relationships with customers and partners. Its comprehensive capabilities, impressive customer references, well-defined roadmap and vision and a highly scalable product suit earn CSG strong ratings for technological excellence and customer impact.
- Quadrant Knowledge Solutions notes: "CSG offers a leading CPQ portfolio, customized specifically for the telecom industry, apart from also having strong third-party partnerships, robust functional capabilities and an extensive customer base."
Beyond these recognitions, CSG is mentioned in the 2023 Gartner Market Guide for CSP Customer Management and Experience Solutions, which CIOs can use to shape their sourcing strategy by understanding the investments and directions of representative vendors. CSG was also mentioned in the 2022 Gartner Market Guide for Revenue Management and Monetization as one of 20 vendors providing a wide variety of solutions, offering different portfolios, deployment/implementation approaches and focus areas for various segments of CSPs.
“Global operators trust CSG to modernize their business because we've demonstrated time and again that we understand their customers’ needs and provide the capabilities they need to drive tangible growth,” said Chad Dunavant, Chief Product & Strategy Officer, CSG. “The breadth and depth of our portfolio support CSPs regardless of their focus on B2C, B2B or B2B2X as we empower them to deliver new services faster than competitors, increase customer satisfaction and boost brand loyalty. This has been our bread and butter for 40+ years and is why industry analysts consistently rank CSG among the leading BSS solution providers across the industry.”
For more information about CSG, visit www.csgi.com.
Gartner, Magic Quadrant for Configure, Price and Quote Application Suites, Mark Lewis, Dayna Radbill, 11 December 2023.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Gartner and Magic Quadrant are registered trademarks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
About CSG
CSG empowers companies to build unforgettable experiences, making it easier for people and businesses to connect with, use and pay for the services they value most. Our customer experience, billing and payments solutions help companies of any size make money and make a difference. With our SaaS solutions, company leaders can take control of their future and tap into guidance along the way from our fiercely committed and forward-thinking CSGers around the world.
Want to be future-ready and a change-maker like the global brands that trust CSG? Visit csgi.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123732657/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
